Comparative Pharmacology
Head-to-head clinical analysis: BAMATE versus BUSPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAMATE versus BUSPAR.
BAMATE vs BUSPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The mechanism of action of BAMATE is not well established; it is thought to involve inhibition of monoamine oxidase (MAO) with preferential inhibition of MAO-B at low doses, leading to increased concentrations of dopamine and other biogenic amines in the brain.
Partial agonist at serotonin 5-HT1A receptors, leading to reduced serotonergic activity; also has antagonist activity at D2 and 5-HT2 receptors.
400 mg orally twice daily
Initial: 7.5 mg orally twice daily; may increase by 5 mg/day every 2-3 days. Usual: 20-30 mg/day in divided doses; max 60 mg/day.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in healthy adults. This short half-life necessitates frequent dosing to maintain therapeutic levels.
Clinical Note
moderateFelbamate + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Felbamate."
Clinical Note
moderateMeprobamate + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Meprobamate is combined with Fluticasone propionate."
Clinical Note
moderateMeprobamate + Haloperidol
"The risk or severity of adverse effects can be increased when Meprobamate is combined with Haloperidol."
Clinical Note
moderate2–3 hours (terminal); clinical context: requires multiple daily dosing; steady-state achieved in ~2 days
BAMATE is primarily excreted renally as unchanged drug (approximately 60-70%) and as glucuronide conjugates (20-30%). Fecal elimination accounts for less than 10%.
Renal: 29–63% (primarily as metabolites, <1% unchanged); Fecal: 34–38%; Biliary: minimal
Category C
Category C
Anxiolytic
Anxiolytic
Felbamate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Felbamate."